Tumor Necrosis Factor-α and Interleukin 4 in Myeloma Cell Precursor Differentiation

References

• Epstein, J. (1992) Myeloma phenotype: Clues to disease origin and manifestation. Hematol. OncoL Clin. North. Am., 6, 249–256.
   PubMed Web of Science ®Google Scholar
• Kubagawa, H., Vogler, L. B., Capla, J. D., Conrad, M. E., Lawton, A. R., and Cooper, M. D. (1979) Studies on the clonal origin of mul-tiple myeloma. J. Erp. Med., 150, 792–807.
   PubMed Web of Science ®Google Scholar
• Pettersson, D., Mellstedt, H., and Holm, G. (1980) Monoclonal B lymphocytes in multiple myeloma. Scand. J. Immunol., 12, 375–382.
   Web of Science ®Google Scholar
• Shimazaki, C., Gotoh, H., Oku, N., Inaba, T., Murakami, S., Oku, N., Itoh, K., Um, Y., Nakagawa, M., and Fujita, N. (1991) Detection of minimal residual myeloma cells by dual parameter analysis of DNA and cytoplasmic immunoglobulin. Acta HaematoL, 85, 20–25.
   PubMed Web of Science ®Google Scholar
• Shimazaki, C., Fried, J., Perez, A. G., Scheinberg, D. A., Atzpodien, J., Wang, C. Y., Wisniewolski, R., and Clarkson, B. D. (1990) Immunophenotypic analysis of lymphocytes and myeloma cells in patients with multiple myeloma. Acta HaematoL, 83, 123–129.
   PubMed Web of Science ®Google Scholar
• Caligaris-Cappio, F., Bergui, L., Tesio, L., Pizzolo, G., Malavasi, F., Chilosi, M., Campana, D., Van Camp, B., and Janossy, G. (1985) Identification of malignant plasma cell precursors in the bone mar-row of multiple myeloma. J. Clin. Invest., 76, 1243–1251.
   Google Scholar
• Grogan, T. M., Dune, B. G. M., Lomen, C., Spier, C., Wirt, D. P., Nagle, R., Wilson, G. S., Richter, L., Vera, E., Maxey, V., McDaniel, K., and Rangel, C. (1987) Delineation of a novel pre-B cell com-ponent in plasma cell myeloma: Immunological, immunophenoki-netic, genotypic, cytologic, cell culture, and kinetic features. Blood, 70, 932–942.
   PubMed Web of Science ®Google Scholar
• Epstein, J., Barlogie, B., Katzmann, J., and Alexanian, R. (1988) Phenotypic heterogeneity in aneuploid multiple myeloma indicates pre-B cell involvement. Blood, 71, 861–865.
   PubMed Web of Science ®Google Scholar
• Berenson, J., Wong, R., Kim, K., Brown, N., and Lichtenstein, A. (1987) Evidence for peripheral blood B lymphocyte but not T-lym-phocyte involvement in multiple myeloma. Blood, 70, 1550–1553.
   PubMed Web of Science ®Google Scholar
• Chiu, E. K. W., Gasneshaguru, K., Hoffbrand, A. V., and Mehta, A. B. (1989) Circulating monoclonal B lymphocytes in multiple myeloma. Br. J. Haemat., 72, 28–31.
   PubMed Web of Science ®Google Scholar
• van Reit, I., Heirman, C., Lacor, P., De Waele, M., Thielemans, K., and van Camp, B. (1989) Detection of monoclonal B lymphocytes in bone marrow and peripheral blood of multiple myeloma patients by immunoglobulin gene rearrangement studies. Br. J. HaematoL, 73, 289–295.
   Google Scholar
• Billadeau, D., Quam, L., Thomas, W., Kay, N., Greipp, P., Kyle, R., Oken, M. M., and Van Ness, B. (1992) Detection and quantita-tion of malignant cells in the peripheral blood of multiple myeloma patients. Blood, 80, 1818–1824.
   Google Scholar
• Kawano, M., Hirano, T., Matsuda, T., Taga, T., Horii, Y., Asaoku, H., Tang, B., Tanabe, 0., Tanaka, H., Kuramoto, A., and Kishimoto, T. (1988) Autocrine generation and requirement of BSF-211L-6 for human multiple myelomas. Nature, 332, 83–85.
   Google Scholar
• Klein, B., Zhang, X. G., Jourdan, M., Content, J., Houssiau, F., Aarden, L., Piechaczyk, M., and Bataille, R. (1989) Paracrine rather than autocrine regulation of myeloma-cell growth and differentia-tion by interleukin-6. Blood, 73, 517–526.
   PubMed Web of Science ®Google Scholar
• Zhang, X. G., Bataille, R., Jourdan, M., Saeland, S., Banchereau, J., Mannoni, P., and Klein, B. (1990) Granulocyte-macrophage colony stimulating factor synergizes with interleukin-6 in supporting the proliferation of human myeloma cells. Blood, 72, 2599–2605.
   Google Scholar
• Sawamura, M., Murakami, H., Tamura, J., Matsushima, T., Sato, S., Naruse, T., and Tsuchiya, J. (1994) Tumour necrosis factor-a and interleukin 4 promote the differentiation of myeloma cell pre-cursors in multiple myeloma. Br. J. HaematoL, 88, 17–23.
   Web of Science ®Google Scholar
• Dude, B. G. M. and Salmon, S. E. (1975) A clinical staging system for multiple myeloma. Cancer, 36, 842–854.
   Google Scholar
• Lichtenstein, A., Berenson, J., Norman, D., Chang, M. P., and Carlile, A. (1989) Production of cytoldnes by bone marrow cells ob-tained from patients with multiple myeloma. Blood, 74, 1266–73.
   PubMed Web of Science ®Google Scholar
• Carter, A., Merchav, S., Silvian-Draxler, I., and Tatarsky, I. (1990) The role of interleukin-1 and tumour necrosis factor-alpha in human multiple myeloma. Br. J. HaematoL, 74,424–431.
   Web of Science ®Google Scholar
• Hata, H., Matsuzaki, H., and Takatsuki, K. (1990) Autocrine growth by two cytoldnes, interleukin-6 and tumor necrosis factor alpha, in the myeloma cell line KHM-1A. Acta Haemat., 83, 133–136.
   PubMed Web of Science ®Google Scholar
• Sonneveld, P., Schoester, M., and de Leeuw, K. (1991) In vitro Ig-synthesis and proliferative activity in multiple myeloma are stimu-lated by different growth factors. Br. J. HaematoL, 79, 589–594.
   Web of Science ®Google Scholar
• Tanabe, 0., Kawano, M., Tanaka, H., Iwato, K., Asaoku, H., Ishikawa, H., Nobuyoshi, M., Hirano, T., Kishimoto, T., and Kuramoto, A. (1989) BSF-211L-6 does not augment Ig secretion but stimulates proliferation in myeloma cells. Am. J. HematoL, 31, 258–262.
   Google Scholar
• Herrmann, F., Andreeff, M., Gross, H. J., Brach, M. A., Lubbert, M., and Mertelsmann, R. (1991) Interleukin-4 inhibits growth of multiple myeloma by suppressing interleukin-6 expression. Blood, 78, 2070–2074.
   PubMed Web of Science ®Google Scholar
• Taylor, C. W., Grogan, T. M., and Salmon, S. E. (1990) Effects of interleukin-4 on the in vitro growth of human lymphoid and plasma cell neoplasms. Blood, 75, 1114–1118.
   PubMed Web of Science ®Google Scholar
• Famularo, G., Giacomelli, R., Di Giovanni, S., Sacchetti, S., and Tonietti, G. (1991) Cytokine production in patients with monoclonal gammopathies. J. Clini. Lab. ImmunoL, 34, 63–69.
   PubMedGoogle Scholar
• Barlogie, B., Epstein, J., Selvanayagam, P., and Alexanian, R. (1989) Plasma cell myeloma. New biological insights and advances in therapy. Blood, 73, 865–879.
   PubMed Web of Science ®Google Scholar
• Caligaris-Cappio, F., Gregoretti, M. G., Ghia, P., and Bergui, L. (1992) In vitro growth of human multiple myeloma: Implications for biology and therapy. HematoL OncoL Clin. North. Am., 6, 257–271.
   Google Scholar
• Bergui, L., Schena, M., Gaidano, G, Riva, M., and Caligalis-Cappio, F. (1989) Interleukin 3 and interleukin 6 synergistically promote the proliferation and differentiation of malignant plasma cell precursors in multiple myeloma. J. Exp. Med., 170, 613–618.
   Google Scholar
• Tokumine, Y., Nishimori, Y., Shibayama, H., Shibano, M., Tagawa, S., Machii, T., and Kitani, T. (1993) Failure of IL-3 plus IL-6 to in- duce the proliferation and differentiation of malignant plasma cell precursors from peripheral blood in multiple myeloma. Leukemia, 7, 333–335.
   PubMed Web of Science ®Google Scholar
• Goto, H., Shimazaki, C., Ashihara, E., Ohkawa, K., Oku, N., Inaba, T., Muralcami, S., Fujita, N., and Nakagawa, M. (1992) Effects of interleulcin-3 and interleukin-6 on peripheral blood cells from mul-tiple myeloma patients and their clinical significance. Acta HaematoL, 88, 129–135.
   PubMed Web of Science ®Google Scholar
• Klein, B., Zhang, X. G., Lu, Z. Y., and Bataille, R. (1995) Interleukin-6 in human multiple myeloma. Blood, 85, 863–872.
   PubMed Web of Science ®Google Scholar
• Stewart, A. K. and Schwartz, R. S. (1994) Immunoglobulin V re-gions and the B cell. Blood, 83, 1717–1730.
   Google Scholar
• Witzig, T., Gonchoroff, N., Katzmann, J., Therneau, T., Kyle, R., and Greipp, P. (1988) Peripheral blood labeling indices are a mea-sure of disease activity in patients with monoclonal gammopathies. J. Clin. OncoL, 6, 1041–1046.
   Web of Science ®Google Scholar
• Witzig, T. E., Gonchoroff, N. J., Ahmann, G. A., Katzmann, J. A., and Greipp, P. R. (1991) T cell depletion using anti-CD2-coated magnetic beads simplifies the detection of peripheral blood plasma cells. J. ImmunoL Methods, 144, 253–256.
   PubMed Web of Science ®Google Scholar
• Witzig, T. E., Kyle, R. A., and Greipp, P. R. (1992) Circulating pe-ripheral blood plasma cells in multiple myeloma. Curr. Top. MicrobioL ImmunoL, 182, 195–199.
   PubMedGoogle Scholar
• Jensen, G. S., Mant, M. J., Belch, A. J., Berenson, J. R., Ruether, B. A., and Pilarski, L. M. (1991) Selective expression of CD45 iso-forms defines CALLA + monoclonal B lineage cells in peripheral blood from myeloma patients as late stage B cells. Blood, 78, 711–719.
   PubMed Web of Science ®Google Scholar
• Corradini, P., Boccadoro, M., Voena, C., and Pileri, A. (1993) Evidence for a bone marrow B cell transcribing malignant plasma cell Val joined to Cp. sequence in immunoglobulin (IgG)- and IgA-secreting multiple myelomas. J. Exp. Med., 178, 1091–1096.
   PubMed Web of Science ®Google Scholar
• Barlogie, B., Alexanian, R., Pershouse, M., Smallwood, L., and Smith, L. (1985) Cytoplasmic immunoglobulin content in multiple myeloma. J. Clin. Invest., 76, 765–769.
   Google Scholar
• Potter, M. (1992) Perspectives on the origins of multiple myeloma and plasmacytomas in mice. HematoL OncoL Clin. North. Am, 6, 211–223.
   Web of Science ®Google Scholar
• Epstein, J. H., Xiao, H. Q., and He, X. Y. (1990) Markers of multi-ple hematopoietic-cell lineages in multiple myeloma. N. Engl. J. Med., 322,664–668.
   Google Scholar
• Billadeau, D., Ahmann, G., Greipp, P., and van Ness, B. (1993) The bone marrow of multiple myeloma patients contains B cell popula-tions at different stages of differentiation that are clonally related to the malignant plasma cell. J. Exp. Med. 178, 1023–1031.
   PubMed Web of Science ®Google Scholar
• Zhang, X. G., Gaillard, J. P., Robillard, N., Lu, Z. Y., Gu, Z. J., Jourdan, M., Boiron, J. M., Bataille, R., and Klein, B. (1994) Reproducible obtaining of human myeloma cell lines as a model for tumor stem cell study in human multiple myeloma. Blood, 83, 3654–3663.
   PubMed Web of Science ®Google Scholar
• Bakkus, M. H. C., Heirman, C., van Riet, I., van Camp, B., and Thielemans, K. (1992) Evidence that multiple myeloma Ig heavy chain VDJ genes contain somatic mutations but show no intraclonal variation. Blood, 80, 2326–2335.
   Google Scholar
• Pilarski, L. M. and Belch, A. R. (1993) Circulating monoclonal B cells expressing P glycoprotein may be a reservoir of multidrug-re-sistant disease in multiple myeloma. Blood, 83, 724–736.
   Web of Science ®Google Scholar
• Vescio, R. A., Hong, C. H., Cao, J., Kim, A., Schiller, G. J., Lichtenstein, A. K., Berenson, R. J., and Berenson, J. R. (1994) The hematopoietic stem cell antigen, CD34, is not expressed on the ma-lignant cells in multiple myeloma. Blood, 84, 3283–3290.
   PubMed Web of Science ®Google Scholar